These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A guide to the treatment of lower respiratory tract infections. Vogel F Drugs; 1995 Jul; 50(1):62-72. PubMed ID: 7588090 [TBL] [Abstract][Full Text] [Related]
4. Antimicrobial agents: the old and the new. Neu HC Am J Infect Control; 1989 Oct; 17(5):276-85. PubMed ID: 2683886 [TBL] [Abstract][Full Text] [Related]
5. Sparfloxacin: potential clinical and economic impact in the treatment of respiratory infections. Stein GE; Havlichek DH Pharmacotherapy; 1997; 17(6):1139-47. PubMed ID: 9399598 [TBL] [Abstract][Full Text] [Related]
6. Newer oral antimicrobials for resistant respiratory tract pathogens. Which show the most promise? Stein GE; Havlichek DH Postgrad Med; 1998 Jun; 103(6):67-70, 74-6. PubMed ID: 9633543 [TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomics of antimicrobial therapy. Paladino JA Am J Health Syst Pharm; 1999 Nov; 56(22 Suppl 3):S25-8. PubMed ID: 10580738 [TBL] [Abstract][Full Text] [Related]
9. Duration of intravenous therapy and hospital stay according to choice of empirical antimicrobial treatment for community-acquired respiratory infection. Laing RB; Mackenzie AR; Shaw H; Gould IM; Douglas JG Int J Antimicrob Agents; 1999 Sep; 13(1):53-6. PubMed ID: 10563405 [TBL] [Abstract][Full Text] [Related]
10. Potential improvements in therapeutic options for mycoplasmal respiratory infections. Bébéar C; Dupon M; Renaudin H; de Barbeyrac B Clin Infect Dis; 1993 Aug; 17 Suppl 1():S202-7. PubMed ID: 8399917 [TBL] [Abstract][Full Text] [Related]
11. Use of a treatment protocol in the management of community-acquired lower respiratory tract infection. Al-Eidan FA; McElnay JC; Scott MG; Kearney MP; Corrigan J; McConnell JB J Antimicrob Chemother; 2000 Mar; 45(3):387-94. PubMed ID: 10702564 [TBL] [Abstract][Full Text] [Related]
12. Antibiotic treatment of ophthalmic infection: new developments. Andrews V J Hosp Infect; 1995 Jun; 30 Suppl():268-74. PubMed ID: 7560961 [TBL] [Abstract][Full Text] [Related]
13. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. Tsutsui A; Yahara K; Shibayama K J Infect Chemother; 2018 Jun; 24(6):414-421. PubMed ID: 29428566 [TBL] [Abstract][Full Text] [Related]
14. The role of newer oral cephalosporins, fluoroquinolones, and macrolides in the treatment of pediatric infections. Rodriguez WJ; Wiedermann BL Adv Pediatr Infect Dis; 1994; 9():125-59. PubMed ID: 8123221 [No Abstract] [Full Text] [Related]
15. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Scott LJ; Ormrod D; Goa KL Drugs; 2001; 61(10):1455-500. PubMed ID: 11558834 [TBL] [Abstract][Full Text] [Related]
17. Perspectives on newer oral antimicrobials: what do they add? Harrison CJ Pediatr Infect Dis J; 1995 May; 14(5):436-44. PubMed ID: 7638034 [TBL] [Abstract][Full Text] [Related]
18. How do the newer oral antimicrobials stack up against traditional agents? Gleckman R; De La Rosa G Postgrad Med; 1998 Oct; 104(4):119-22, 125-6. PubMed ID: 9793559 [TBL] [Abstract][Full Text] [Related]
19. Sequential switch therapy for lower respiratory tract infections: a European perspective. Nathwani D Chest; 1998 Mar; 113(3 Suppl):211S-218S. PubMed ID: 9515895 [TBL] [Abstract][Full Text] [Related]
20. How should we evaluate new anti-infectives for respiratory tract infections? Paladino JA Can Respir J; 1999; 6 Suppl A():31A-4A. PubMed ID: 10202231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]